SCHEMBL3642463

SCHEMBL3642463

CNC(=O)c1ccc(-c2ccc3cc(C(=O)O)[nH]c3c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.52
▸ EIF4A3 P38919 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ DAO P14920 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ SRD5A2 P31213 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ CRBN Q96SW2 1/20 0.45
▸ ROCK2 O75116 1/20 0.44
▸ ROCK1 Q13464 1/20 0.44
▸ PIN1 Q13526 1/20 0.43
▸ RIPK1 Q13546 1/20 0.43
▸ GPR35 Q9HC97 1/20 0.43
▸ DGAT1 O75907 1/20 0.43
▸ GRIK1 P39086 1/20 0.42
▸ GRIK2 Q13002 1/20 0.42
▸ GRIK3 Q13003 1/20 0.42
▸ PRMT1 Q99873 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640951 0.89 PIN1 (0.54) KDM4EMAPTDAOHPGDSRD5A2
SCHEMBL3638893 0.88 ALOX15 (0.49) ALOX15EIF4A3KDM4EMAPTDAO
SCHEMBL7222628 0.81 PIN1 (0.61) EIF4A3KDM4EMAPTDAOHPGD
SCHEMBL3389181 0.81 HSD17B10 (0.66) EIF4A3KDM4EMAPTDAOHPGD
SCHEMBL20495000 0.80 EIF4A3 (0.52) EIF4A3KDM4EMAPTDAOHPGD
SCHEMBL30071418 0.80 EIF4A3 (0.52) EIF4A3KDM4EMAPTDAOHPGD
SCHEMBL6515240 0.80 PIN1 (0.59) ALOX15EIF4A3KDM4EMAPTDAO
SCHEMBL30071340 0.79 SMAD3 (0.60) EIF4A3KDM4EMAPTDAOHPGD
SCHEMBL20494223 0.79 SMAD3 (0.60) EIF4A3KDM4EMAPTDAOHPGD
SCHEMBL23165181 0.79 ALOX15 (0.61) ALOX15ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167077-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-31 — — EP claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 ALOX15 32/4885EIF4A3 3270/4885KDM4E 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback